Publications. Multiple Sclerosis and Related Disorders Matthijs Versteegh 7/28/25 Multiple Sclerosis and Related Disorders Matthijs Versteegh 7/28/25 Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine Read More Multiple Sclerosis and Related Disorders Matthijs Versteegh 10/30/23 Multiple Sclerosis and Related Disorders Matthijs Versteegh 10/30/23 Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model Read More
Multiple Sclerosis and Related Disorders Matthijs Versteegh 7/28/25 Multiple Sclerosis and Related Disorders Matthijs Versteegh 7/28/25 Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine Read More
Multiple Sclerosis and Related Disorders Matthijs Versteegh 10/30/23 Multiple Sclerosis and Related Disorders Matthijs Versteegh 10/30/23 Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model Read More
